Jean Bergeron is a physician acting as consultant and clinical scientist at the, Endocrinology and Nephrology Research Unit, Centre de recherche du CHU de Québec – Université Laval, as well as Professor at the Molecular Biology, Medical Biochimistry and Pathology Department, Faculty of Medicine, Laval University. He is member of the Medical Biochimistry Unit (Department of Laboratory Medicine) and chief of the Lipid clinic (Department of Medicine) of the CHU de Québec-Université Laval. He is also Secretary for the Société Québécoise de Lipidologie, Nutrition et Métabolisme (SQLNM), a scientific society from which he received in 2012 a recognition award, Le prix des Fondateurs Jean Davignon et Paul-J. Lupien, for his outstanding contribution in the field of lipidology. As specialist in laboratory medicine and lipidology, he supervises the CHU de Québec – Laval University clinical lipid laboratory performing lipoprotein, lipid and gene analyses.

 

Interest in clinical research

During his career, he has been dedicated to a better understanding of clinical and biological expressions of primary and secondary hyperlipidemia. He has also participated in the development and application of up to date lipid guidelines for clinicians and contributed to the characterization of new metabolic markers related to atherosclerosis and heart disease. He participated to numerous clinical trials using statins and new emergent therapies in lipoprotein metabolism.

 

Actual clinical research

More recently, he is involved in research on statin-generated myopathy, including identification of blood or genetic markers related to statin side effect and development of clinical tools for a better support to patients suffering from this condition. He is involved in the Canadian Familial Hypercholesterolemia registry. Finally, he is principal investigator in several clinical trials using PCSK9 inhibitors, anti-sense oligonucleotides, ANGPTL-3 inhibitors, and in some cases, gene therapy for very severe hypercholesterolemia or patients at very high CV risk for premature atherosclerotic heart disease.

 

CHUL
2705, boulevard Laurier
C-00-224
Québec, Québec
Canada G1V 4G2
+1 418-525-4444, extension 42162
jean.bergeron@crchudequeb...

Latest news

Data not available

231 entries « ‹ 1 of 24 › »

Rosenson RS, Gaudet D, Ballantyne CM, Baum SJ, Bergeron J, Kershaw EE, Moriarty PM, Rubba P, Whitcomb DC, Banerjee P, Gewitz A, Gonzaga-Jauregui C, McGinniss J, Ponda MP, Pordy R, Zhao J, Rader DJ

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial

Journal Article

Nat Med, 29 (3), 2023.

Abstract | Links:

Paquette C, Careau AM, Bergeron J, Carpentier C, Claveau J

A case of eruptive xanthomas associated with pregnancy unmasking a G188E heterozygous mutation of the lipoprotein lipase gene: A case report

Journal Article

SAGE Open Med Case Rep, 10 , 2022.

Abstract | Links:

Gaudet D, Ruzza A, Bridges I, Maruff P, Schembri A, Hamer A, Mach F, Bergeron J, Gaudet I, Pierre JS, Kastelein JJP, Hovingh GK, Wiegman A, Raal FJ, Santos RD

Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia

Journal Article

J Clin Lipidol, 16 (5), 2022.

Abstract | Links:

Santos RD, Ruzza A, Hovingh GK, Stefanutti C, Mach F, Descamps OS, Bergeron J, Wang B, Bartuli A, Buonuomo PS, Greber-Platzer S, Luirink I, Bhatia AK, Raal FJ, Kastelein JJP, Wiegman A, Gaudet D

Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT

Journal Article

Lancet Diabetes Endocrinol, 10 (10), 2022.

Abstract | Links:

Gupta M, Mancini GBJ, Wani RJ, Ahooja V, Bergeron J, Manjoo P, Pandey AS, Reiner M, Beltran J, Oliveira T, Mackinnon ES

Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study

Journal Article

CJC Open, 4 (6), 2022.

Abstract | Links:

Clément AA, Lacaille M, Lounis MA, Biertho LD, Richard D, Lemieux I, Bergeron J, Mounier C, Joanisse DR, Mauriège P

Intra-abdominal adipose depot variation in adipogenesis, lipogenesis, angiogenesis, and fibrosis gene expression and relationships with insulin resistance and inflammation in premenopausal women with severe obesity

Journal Article

J Physiol Biochem, 78 (2), 2022.

Abstract | Links:

Roy G, Couture P, Genest J, Ruel I, Baass A, Bergeron J, Brisson D, Brunham LR, Cermakova L, Gaudet D, Khoury E, Laflamme N, Kennedy BA, Hegele RA, Drouin-Chartier JP

Influence of the LDL-Receptor Genotype on Statin Response in Heterozygous Familial Hypercholesterolemia: Insights From the Canadian FH Registry

Journal Article

Can J Cardiol, 38 (3), 2022.

Abstract | Links:

Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Baccara-Dinet MT, Zhao J, Donahue S, Ali S, Manvelian G, Pordy R

Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial

Journal Article

J Clin Lipidol, 14 (1), 2020.

Abstract | Links:

Gangloff A, Bergeron J, Lemieux I, Despres JP

Adiposity, lifestyle and vitamin D levels: the quest for answers

Journal Article

Int J Obes (Lond), 44 (7), 2020.

| Links:

Gangloff A, Bergeron J, Lemieux I, Tremblay A, Poirier P, Almeras N, Despres JP

Relationships between circulating 25(OH) vitamin D, leptin levels and visceral adipose tissue volume: results from a 1-year lifestyle intervention program in men with visceral obesity

Journal Article

Int J Obes (Lond), 44 (2), 2020.

Abstract | Links:

231 entries « ‹ 1 of 24 › »
Signaler des ajouts ou des modifications